GlassScriptPhysician profile
Angela R Eklund
NPI 1245434802
$8,798.51
in general payments reported to CMS, 2019-2025
35 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $294 · 2021: $529 · 2022: $4,084 · 2023: $1,005 · 2024: $1,290 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,723.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eagle Pharmaceuticals, INC. | $3,384.00 | 2022 | |
| Novo Nordisk INC | $968.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $555.70 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $447.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $396.89 | 2020-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $387.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.54 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $290.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $230.19 | 2023-2025 | Proclaim, Eterna |
| Astellas Pharma US INC | $226.99 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $215.10 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $207.44 | 2019-2024 | Spravato |
| Abbvie INC. | $150.82 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.76 | 2022-2024 | |
| Dexcom, INC. | $133.08 | 2023-2025 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.67 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $68.12 | 2019-2022 | |
| Grifols USA, LLC | $64.87 | 2024 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $63.01 | 2025 | Inspire |
| Radius Health, INC. | $58.35 | 2020-2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $50.57 | 2021-2022 | |
| Esperion Therapeutics, INC. | $39.08 | 2021-2023 | Nexletol |
| Ibsa Pharma INC. | $32.08 | 2019-2023 | Tirosint, Licart |
| Melinta Therapeutics, LLC | $26.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.35 | 2022 | |
| Rgh Enterprises LLC | $22.33 | 2025 | |
| Genentech USA, INC. | $21.06 | 2019 | |
| Horizon Therapeutics Plc | $19.54 | 2022 | |
| Axonics, INC. | $18.38 | 2020 | |
| Sumitomo Pharma America, INC. | $16.37 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $13.84 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $13.23 | 2023 | Quviviq |
| Bardy Diagnostics, INC. | $12.12 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.65 | 2020 | |
| Allergan, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Eklund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.